-
公开(公告)号：US10751168B2
公开(公告)日：2020-08-25
申请号：US15567053
申请日：2016-01-20
Applicant: KOWA COMPANY, LTD.
Inventor： Genyo Midorikawa
Abstract: An intraocular lens insertion apparatus includes an apparatus body configured to include a housing member for housing an intraocular lens and an insertion tube member for ejecting the intraocular lens into an eyeball of a patient, a plunger configured to move in the apparatus body, and a hook member formed on the apparatus body for a user of the intraocular lens insertion apparatus to hook a finger when the user moves the plunger. The plunger is moved to a side of the insertion tube member, the intraocular lens housed in the housing member is pushed by a distal end of the plunger, and the intraocular lens is ejected from the insertion tube member, and a connecting member configured to connect an operability enhancing member for enhancing an operability of the plunger when the plunger is moved with the apparatus body is provided for the apparatus body.
-
公开(公告)号：US20200246314A1
公开(公告)日：2020-08-06
申请号：US16853121
申请日：2020-04-20
Applicant: KOWA COMPANY, LTD.
Inventor： Yuta Inokuchi , Toshiaki Takizawa
IPC: A61K31/423 , A61K31/455
Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.
-
公开(公告)号：US10701258B2
公开(公告)日：2020-06-30
申请号：US16474620
申请日：2018-01-30
Applicant: KOWA COMPANY, LTD.
Inventor： Tomohisa Azegami
Abstract: [Problem] To enable imaging to be performed with appropriate timing.[Solution] In a camera manipulation device 1 according to the present invention, a trigger signal T12 is issued and imaging is begun when a prescribed command is transmitted from a control circuit side to an imaging unit side (see S12). Because the issuance of such trigger signal T12 is not accepted before a character reception start command is issued, it is possible to perform imaging with appropriate timing.
-
24.发明申请
公开(公告)号：US20200151909A1
公开(公告)日：2020-05-14
申请号：US16609669
申请日：2018-04-27
Applicant: KOWA COMPANY, LTD.
Inventor： Katsumi YABUSAKI
IPC: G06T7/90
Abstract: Provided are an analysis evaluation method and device, and a computer program for the state of a subject surface in a still image. The method includes: a step of acquiring color information of each pixel in a predetermined region in a still image, a step of calculating a numerical value indicating a diversity of color from the acquired color information, a step of calculating an average value of the color information, and a step of calculating a coefficient of variation on the basis of the calculated numerical value indicating the diversity of color and the calculated average value of the color information. Herein, the coefficient of variation is used as an index for evaluating the surface state of an object.
-
公开(公告)号：US20200022960A1
公开(公告)日：2020-01-23
申请号：US16477416
申请日：2018-01-11
Applicant: Kowa Company, Ltd.
Inventor： Yusuke Sasaki , Masato Asahiyama , Toshiya Tanaka
IPC: A61K31/423 , A61P1/16
Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) α agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
公开(公告)号：USD863060S1
公开(公告)日：2019-10-15
申请号：US29596298
申请日：2017-03-07
Applicant: KOWA COMPANY, LTD.
Designer： Haruyasu Abe , Masato Seki
-
27.发明申请
公开(公告)号：US20190282139A1
公开(公告)日：2019-09-19
申请号：US16345107
申请日：2017-11-02
Applicant: Kowa Company, Ltd.
Inventor： Takaharu ASANO , Katsumi YABUSAKI
IPC: A61B5/145 , A61B5/1455
Abstract: Provided are an in-blood component measurement method, an in-blood component measurement device, and an in-blood component measurement program, enabling more accurate measurement of a proportion of glycohemoglobin in the total hemoglobin concentration in blood. The in-blood component measurement method is designed to have a constitution including the steps of irradiating, with near-infrared light, blood that is a target to be measured for a proportion of glycohemoglobin in the total hemoglobin concentration in blood, receiving transmitted light of the near-infrared light passing through the blood, measuring an absorption spectrum of the blood on the basis of the transmitted light received, and calculating the proportion for the blood that is the target of measurement by comparing absorbance at a first wavelength range including 1450 nm in the measured absorption spectrum to absorbance at the first wavelength range in the absorption spectrum of blood in which the proportion is already known.
-
公开(公告)号：US20190167645A1
公开(公告)日：2019-06-06
申请号：US16272050
申请日：2019-02-11
Applicant: KOWA COMPANY, LTD.
Inventor： Toshiaki Takizawa , Yasunobu Yoshinaka
IPC: A61K31/423 , A61K45/06 , A61K31/397
Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.
-
公开(公告)号：US20190117059A1
公开(公告)日：2019-04-25
申请号：US16210038
申请日：2018-12-05
Applicant: KOWA COMPANY, LTD.
Inventor： Satoshi SHIMADA , Takuya HARA
Abstract: In a perimetry to be conducted, designating an inspection region through a region designator, a perimeter is configured to set a required time of the perimetry (upper limit time) through an upper limit condition setter and to determine total number or positions of stimulus presentation spots based upon the upper limit time. In such a configuration, an examinee knows the time to finish the inspection, and is able to highly keep his (her) concentration in comparison with a case where the required time is not known, thereby improving precision of the inspection.
-
公开(公告)号：US20180289719A1
公开(公告)日：2018-10-11
申请号：US16005136
申请日：2018-06-11
Applicant: KOWA COMPANY, LTD.
Inventor： Isamu SAWAI
IPC: A61K31/551 , A61K9/08 , A61K31/5575 , A61P27/06 , C08L23/12 , A61K45/06 , A61K47/14 , A61K9/00 , A61K31/18 , A61K31/502
Abstract: A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a prostaglandin.
